DSMC didn't stop the trial at the safety review at 120 patients. Everyone needs to be prepared for the DSMC deciding not to stop the trial at the interim review of 195 patients and to continue the trial to completion of 390 patients. I hope that's not true but it is still a real possibility.
Market Data 
Markets 
